Sanofi: Disclosure of trading in own shares

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...

Q3 2026: double-digit growth in sales and business EPSFY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3% at CER1 and business earnings per share (EPS)2 of €3.55 Pharma launches...